GFM
CADL icon

GF Fund Management’s Candel Therapeutics CADL Stock Holding History

GF Fund Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6K Buy
1,224
+146
+14% +$795 ﹤0.01% 597
2025
Q4 		$6.09K Buy
+1,078
New +$5.8K ﹤0.01% 612

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GF Fund Management's CADL Position: Q1 2026 in Review

GF Fund Management increased its Candel Therapeutics (CADL) stake by 14% in Q1 2026, buying an estimated $795 and bringing the position to 1,224 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #597.

GF Fund Management first reported a position in CADL in Q4 2025 and has held it in 2 quarters since. The position peaked at $6.09K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • GF Fund Management held 1,224 shares of Candel Therapeutics worth $6K as of Q1 2026.
  • GF Fund Management bought 146 Candel Therapeutics shares in Q1 2026, an estimated $795.
  • Candel Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #597 holding.
  • GF Fund Management first reported a position in Candel Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • GF Fund Management's Candel Therapeutics position peaked at $6.09K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.